Decompensated Heart FailureNCT07506499
Cardiac Rehabilitation in Decompensated Heart Failure
A study testing Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment in people with Decompensated Heart Failure, run by Beni-Suef University at 1 site in Egypt.
Trial summary
Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Read more about this study
- Who is it for?
- Ages 45 to 65 years
- Conditions the study is for
- Decompensated Heart Failure
- What is being tested?
- Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 135 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2026to 1 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged from 45 to 65 years old
- Both sexes
- Hospitalized heart failure patients with ejection fraction < 40%
- Conscious and cooperative
- Able to participate in training actively
Who cannot join
- Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)
- Uncontrolled life-threatening arrhythmias
- Severe valvular heart disease requiring urgent surgery
- Pregnancy
- End-stage renal disease requiring dialysis
- Significant pulmonary diseases such as pulmonary arterial hypertension,
Show all 10Show fewer
- Implanted pacemaker
- Clinically significant peripheral vascular disease
- Severe anemia
- Exercise-induced angina or ST-segment changes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Beni-Suef University Hospital
Banī Suwayf, Beni-Suef Governorate
About this study
Official title: Effect of Cardiac Rehabilitation in Patients With Decompensated Heart Failure
Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise.
This randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone.
The intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.
Read the detailed description
Heart failure is a progressive clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands. Decompensated heart failure represents an acute or subacute deterioration requiring hospitalization and is associated with significant morbidity, prolonged hospital stays, and high readmission rates. Beyond the primary cardiac impairment, patients with decompensated heart failure commonly develop secondary systemic consequences, including respiratory muscle dysfunction and peripheral skeletal muscle abnormalities, both of which contribute independently to exercise intolerance, symptom burden, and poor functional outcomes.
Inspiratory muscle weakness has been identified in approximately 30-50% of patients with heart failure and is believed to result from a combination of diaphragmatic underperfusion, chronic hyperventilation, and systemic inflammatory and catabolic processes. This weakness leads to increased work of breathing, ventilatory inefficiency, and heightened perception of dyspnea, creating a vicious cycle that further limits physical activity and accelerates functional decline. Inspiratory muscle training (IMT) targets this mechanism by applying progressive resistive loading to the inspiratory muscles, promoting improvements in diaphragmatic strength, ventilatory efficiency, and autonomic modulation. Several studies have demonstrated favorable effects of IMT on inspiratory muscle performance, exercise capacity, and quality of life in stable heart failure populations; however, evidence regarding its application during the acute decompensated phase remains limited.
Peripheral skeletal muscle dysfunction in heart failure is characterized by a shift from type I oxidative to type II glycolytic muscle fibers, reduced mitochondrial density, impaired oxygen utilization, and muscle atrophy driven by disuse, neurohormonal activation, and systemic inflammation. These changes are particularly pronounced during periods of decompensation and prolonged bed rest. Functional electrical stimulation (FES) offers a passive approach to muscle activation that bypasses the cardiovascular demand of voluntary exercise, making it a potentially suitable intervention for hemodynamically unstable or severely deconditioned patients. FES-induced muscle contractions have been shown to improve local blood flow, enhance oxidative enzyme activity, and promote favorable fiber-type remodeling in heart failure populations.
Despite the established individual benefits of IMT and FES, no study to date has investigated the combined application of these two modalities in patients hospitalized with decompensated heart failure. The physiological rationale for combining them is based on the concept of addressing both central (respiratory muscle) and peripheral (skeletal muscle) components of exercise intolerance simultaneously, which may produce additive or synergistic improvements in functional capacity and clinical outcomes compared to either intervention alone.
This study hypothesizes that the addition of combined IMT and FES to routine medical treatment will result in greater improvements in cardiac function, inspiratory muscle strength, and functional capacity compared to IMT alone or medical treatment alone in patients with decompensated heart failure. The findings may contribute to the development of early, comprehensive cardiac rehabilitation strategies for this high-risk population.
- Conditions
- Decompensated Heart Failure
- Being tested
- Inspiratory Muscle Trainer, Functional Electrical Stimulation, Standard medical treatment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inspiratory Muscle TrainerDevice
Inspiratory muscle training performed using a threshold inspiratory muscle trainer at 30% of maximal inspiratory pressure for 30 minutes per session, 4-5 sessions per week for four weeks.
Functional Electrical StimulationDevice
Functional electrical stimulation will be applied to the quadriceps and gastrocnemius muscles of both lower limbs using surface electrodes. Electrical stimulation will be delivered at a frequency of 10 Hz, pulse width of 150 ms, and 20 seconds on / 20 seconds off duty cycle for approximately 45 minutes per session.
Standard medical treatmentOther
Participants will receive routine pharmacological treatment for heart failure according to hospital guidelines.
| Study group | Role | What they receive |
|---|---|---|
| IMT + FES Group | Experimental | Participants receive routine medical treatment combined with inspiratory muscle training and functional electrical stimulation of the lower limb muscles as part of a cardiac rehabilitation program. Receives: Device: Inspiratory Muscle Trainer; Device: Functional Electrical Stimulation; Other: Standard medical treatment |
| IMT Group | Active comparator | Participants receive routine medical treatment combined with inspiratory muscle training. Receives: Device: Inspiratory Muscle Trainer; Other: Standard medical treatment |
| Control Group | Active comparator | Participants receive routine medical treatment only. Receives: Other: Standard medical treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Inspiratory Pressure
Inspiratory muscle strength will be assessed by measuring maximum inspiratory pressure (MIP) using a maximum inspiratory pressure meter.
Measured: Baseline and 4 weeks
Secondary outcomes (9)
Dyspnea Severity
Dyspnea severity will be assessed using the Modified Medical Research Council Dyspnea Scale (mMRC), which grades the impact of breathlessness on daily activities on a scale from 0 (minimum) to 4 (maximum), where higher scores indicate worse dyspnea severity.
Measured: Baseline and 4 weeks
Quality of Life (Minnesota Living with Heart Failure Questionnaire Score)
Quality of life will be evaluated using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), a 21-item questionnaire assessing the impact of heart failure on physical, emotional, and social aspects of daily life. Total scores range from 0 (minimum) to 105 (maximum), where higher scores indicate worse quality of life.
Measured: Baseline and 4 weeks
Functional capacity (6-minute walk test)
Functional capacity will be assessed using the 6-minute walk test (6MWT) by measuring the distance walked in meters.
Measured: Baseline and 4 weeks
Heart Rate
Resting heart rate will be measured in beats per minute (bpm) using a pulse oximeter
Measured: Baseline and 4 weeks
Hand Grip Strength
Hand grip strength will be measured using a hand grip dynamometer to assess peripheral muscle strength.
Measured: Baseline and 4 weeks
Maximum Expiratory Pressure
Expiratory muscle strength will be assessed by measuring maximum expiratory pressure (MEP) using a maximum expiratory pressure meter.
Measured: Baseline and 4 weeks
Length of Hospital Stay
Length of hospital stay will be measured as the number of days from hospital admission to hospital discharge.
Measured: During the hospitalization period (Up to 7 days)
Estimated peak oxygen uptake (VO₂max)
Estimated VO₂max (mL/kg/min) calculated from the Duke Activity Status Index (DASI) using a validated published equation
Measured: Baseline and 4 weeks
Oxygen Saturation (SpO₂)
Peripheral oxygen saturation (SpO₂) will be measured as a percentage (%) at rest using a pulse oximeter
Measured: Baseline and 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study start1 Apr 2026
- Primary completion15 Aug 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Decompensated Heart FailureStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 135 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Salma Abdelfattah Mostafa Elsalhy, Beni-Suef University
- Investigators
- SHERIN HASSAN MEHANI, Professor of Physical Therapy, Principal investigator, Faculty Of Physical Therapy Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07506499
- Sponsor's protocol ID
- CR-HF-BSU
- Status last verified
- Apr 2026
- First submitted
- 5 Mar 2026
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Cardiac Rehabilitation in Patients With Decompensated Heart Failure
- ClinicalTrials.gov ID
- NCT07506499
- Acronym / sponsor ID
- CR-HF-BSU
- Conditions
- Decompensated Heart Failure
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 135 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 15 Aug 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise.
This randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone.
The intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.
Detailed description
Heart failure is a progressive clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands. Decompensated heart failure represents an acute or subacute deterioration requiring hospitalization and is associated with significant morbidity, prolonged hospital stays, and high readmission rates. Beyond the primary cardiac impairment, patients with decompensated heart failure commonly develop secondary systemic consequences, including respiratory muscle dysfunction and peripheral skeletal muscle abnormalities, both of which contribute independently to exercise intolerance, symptom burden, and poor functional outcomes.
Inspiratory muscle weakness has been identified in approximately 30-50% of patients with heart failure and is believed to result from a combination of diaphragmatic underperfusion, chronic hyperventilation, and systemic inflammatory and catabolic processes. This weakness leads to increased work of breathing, ventilatory inefficiency, and heightened perception of dyspnea, creating a vicious cycle that further limits physical activity and accelerates functional decline. Inspiratory muscle training (IMT) targets this mechanism by applying progressive resistive loading to the inspiratory muscles, promoting improvements in diaphragmatic strength, ventilatory efficiency, and autonomic modulation. Several studies have demonstrated favorable effects of IMT on inspiratory muscle performance, exercise capacity, and quality of life in stable heart failure populations; however, evidence regarding its application during the acute decompensated phase remains limited.
Peripheral skeletal muscle dysfunction in heart failure is characterized by a shift from type I oxidative to type II glycolytic muscle fibers, reduced mitochondrial density, impaired oxygen utilization, and muscle atrophy driven by disuse, neurohormonal activation, and systemic inflammation. These changes are particularly pronounced during periods of decompensation and prolonged bed rest. Functional electrical stimulation (FES) offers a passive approach to muscle activation that bypasses the cardiovascular demand of voluntary exercise, making it a potentially suitable intervention for hemodynamically unstable or severely deconditioned patients. FES-induced muscle contractions have been shown to improve local blood flow, enhance oxidative enzyme activity, and promote favorable fiber-type remodeling in heart failure populations.
Despite the established individual benefits of IMT and FES, no study to date has investigated the combined application of these two modalities in patients hospitalized with decompensated heart failure. The physiological rationale for combining them is based on the concept of addressing both central (respiratory muscle) and peripheral (skeletal muscle) components of exercise intolerance simultaneously, which may produce additive or synergistic improvements in functional capacity and clinical outcomes compared to either intervention alone.
This study hypothesizes that the addition of combined IMT and FES to routine medical treatment will result in greater improvements in cardiac function, inspiratory muscle strength, and functional capacity compared to IMT alone or medical treatment alone in patients with decompensated heart failure. The findings may contribute to the development of early, comprehensive cardiac rehabilitation strategies for this high-risk population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| IMT + FES Group | Experimental | Device: Inspiratory Muscle Trainer, Device: Functional Electrical Stimulation, Other: Standard medical treatmentParticipants receive routine medical treatment combined with inspiratory muscle training and functional electrical stimulation of the lower limb muscles as part of a cardiac rehabilitation program. |
| IMT Group | Active comparator | Device: Inspiratory Muscle Trainer, Other: Standard medical treatmentParticipants receive routine medical treatment combined with inspiratory muscle training. |
| Control Group | Active comparator | Other: Standard medical treatmentParticipants receive routine medical treatment only. |
Who may qualify
- Ages
- 45 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Aged from 45 to 65 years old
- Both sexes
- Hospitalized heart failure patients with ejection fraction < 40%
- Conscious and cooperative
- Able to participate in training actively
Key exclusion criteria (10 listed)
- Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)
- Uncontrolled life-threatening arrhythmias
- Severe valvular heart disease requiring urgent surgery
- Pregnancy
- End-stage renal disease requiring dialysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inspiratory Muscle TrainerInspiratory muscle training performed using a threshold inspiratory muscle trainer at 30% of maximal inspiratory pressure for 30 minutes per session, 4-5 sessions per week for four weeks. | Device | IMT + FES Group, IMT Group |
| Functional Electrical StimulationFunctional electrical stimulation will be applied to the quadriceps and gastrocnemius muscles of both lower limbs using surface electrodes. Electrical stimulation will be delivered at a frequency of 10 Hz, pulse width of 150 ms, and 20 seconds on / 20 seconds off duty cycle for approximately 45 minutes per session. | Device | IMT + FES Group |
| Standard medical treatmentParticipants will receive routine pharmacological treatment for heart failure according to hospital guidelines. | Other | Control Group, IMT + FES Group, IMT Group |
Primary outcome
Maximum Inspiratory Pressure
Time frame: Baseline and 4 weeks
Inspiratory muscle strength will be assessed by measuring maximum inspiratory pressure (MIP) using a maximum inspiratory pressure meter.
9 secondary outcomes
Dyspnea Severity
Time frame: Baseline and 4 weeks
Quality of Life (Minnesota Living with Heart Failure Questionnaire Score)
Time frame: Baseline and 4 weeks
Functional capacity (6-minute walk test)
Time frame: Baseline and 4 weeks
Heart Rate
Time frame: Baseline and 4 weeks
Hand Grip Strength
Time frame: Baseline and 4 weeks
Maximum Expiratory Pressure
Time frame: Baseline and 4 weeks
Length of Hospital Stay
Time frame: During the hospitalization period (Up to 7 days)
Estimated peak oxygen uptake (VO₂max)
Time frame: Baseline and 4 weeks
Oxygen Saturation (SpO₂)
Time frame: Baseline and 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Decompensated Heart Failure
RecruitingObservational study
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function
Inflammation Biomarkers, Heart Failure
Not yet recruitingPhase 3
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
Heart Failure, Acute Decompensated Heart Failure
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 3
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Acute Decompensated Heart Failure (ADHF)
Recruiting
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
Acute Decompensated Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
SHERIN HASSAN MEHANI, Professor of Physical Therapy principal investigator
Faculty Of Physical Therapy Beni-Suef University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Inspiratory Muscle Trainer, Functional Electrical Stimulation and Standard medical treatment in people with Decompensated Heart Failure, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Salma mostafa Elsalhy, BSc (+20 1022792745, salmaabdelfattah@pt.bsu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Inspiratory Pressure (time frame: Baseline and 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.